Disarming suppressor cells to improve immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 283, doi. 10.1007/s00262-011-1171-7
- By:
- Publication type:
- Article
Works matching IS 03407004 AND DT 2012 AND VI 61 AND IP 2
Results: 17
1
2
Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 275, doi. 10.1007/s00262-011-1164-6
- By:
- Publication type:
- Article
3
Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 215, doi. 10.1007/s00262-011-1184-2
- By:
- Publication type:
- Article
4
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 255, doi. 10.1007/s00262-011-1161-9
- By:
- Publication type:
- Article
5
Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 289, doi. 10.1007/s00262-011-1181-5
- By:
- Publication type:
- Article
6
Novel insights into the molecular mechanisms of HLA class I abnormalities.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 249, doi. 10.1007/s00262-011-1153-9
- By:
- Publication type:
- Article
7
Potential rescue, survival and differentiation of cancer stem cells and primary non-transformed stem cells by monocyte-induced split anergy in natural killer cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 265, doi. 10.1007/s00262-011-1163-7
- By:
- Publication type:
- Article
8
MicroRNA regulation in cancer-associated fibroblasts.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 231, doi. 10.1007/s00262-011-1139-7
- By:
- Publication type:
- Article
9
Immunological monitoring of the tumor immunoenvironment for clinical trials.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 239, doi. 10.1007/s00262-011-1148-6
- By:
- Publication type:
- Article
10
Interleukin 6 mediates production of interleukin 10 in metastatic melanoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 145, doi. 10.1007/s00262-011-1084-5
- By:
- Publication type:
- Article
11
Regulatory dendritic cells in the tumor immunoenvironment.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 223, doi. 10.1007/s00262-011-1138-8
- By:
- Publication type:
- Article
12
The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 193, doi. 10.1007/s00262-011-1096-1
- By:
- Publication type:
- Article
13
Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 157, doi. 10.1007/s00262-011-1093-4
- By:
- Publication type:
- Article
14
From cell regulation to patient survival: 2nd Cancer immunotherapy and immunomonitoring (CITIM) meeting, Budapest, 2-5 May 2011.
- Published in:
- 2012
- By:
- Publication type:
- Report
15
Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 203, doi. 10.1007/s00262-011-1101-8
- By:
- Publication type:
- Article
16
Exposure of CD34 precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 181, doi. 10.1007/s00262-011-1039-x
- By:
- Publication type:
- Article
17
Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2012, v. 61, n. 2, p. 169, doi. 10.1007/s00262-011-1095-2
- By:
- Publication type:
- Article